Intermede Investment Partners Ltd Has $62.21 Million Position in Allergan PLC. (NYSE:AGN)

Intermede Investment Partners Ltd boosted its position in Allergan PLC. (NYSE:AGN) by 14.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 255,915 shares of the company’s stock after buying an additional 32,754 shares during the period. Allergan PLC. comprises 6.0% of Intermede Investment Partners Ltd’s holdings, making the stock its 2nd largest position. Intermede Investment Partners Ltd owned 0.08% of Allergan PLC. worth $62,210,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. First American Trust FSB purchased a new stake in Allergan PLC. during the first quarter worth approximately $4,081,000. Triangle Securities Wealth Management increased its stake in Allergan PLC. by 8.9% in the first quarter. Triangle Securities Wealth Management now owns 2,043 shares of the company’s stock worth $488,000 after buying an additional 167 shares during the period. Atalanta Sosnoff Capital LLC purchased a new stake in Allergan PLC. during the first quarter worth approximately $25,801,000. Park National Corp OH increased its stake in Allergan PLC. by 6.2% in the first quarter. Park National Corp OH now owns 32,962 shares of the company’s stock worth $7,875,000 after buying an additional 1,925 shares during the period. Finally, Cacti Asset Management LLC increased its stake in Allergan PLC. by 1.3% in the first quarter. Cacti Asset Management LLC now owns 196,920 shares of the company’s stock worth $47,221,000 after buying an additional 2,600 shares during the period. 84.77% of the stock is owned by hedge funds and other institutional investors.

Allergan PLC. (AGN) traded up 0.29% during midday trading on Friday, hitting $232.88. The company had a trading volume of 1,820,899 shares. The stock has a 50 day moving average of $245.93 and a 200 day moving average of $238.13. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The firm has a market cap of $77.85 billion, a price-to-earnings ratio of 7.10 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter last year, the firm earned $3.35 earnings per share. On average, analysts anticipate that Allergan PLC. will post $16.27 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.20%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is presently 9.95%.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by BNB Daily and is owned by of BNB Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.baseball-news-blog.com/2017/08/14/intermede-investment-partners-ltd-buys-32754-shares-of-allergan-plc-nyseagn-updated-updated-updated.html.

A number of research firms recently commented on AGN. Mizuho reaffirmed a “buy” rating and set a $267.00 target price on shares of Allergan PLC. in a report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 price target on Allergan PLC. and gave the company a “buy” rating in a research report on Thursday, August 3rd. Wells Fargo & Company lifted their price target on Allergan PLC. to $278.00 and gave the company an “outperform” rating in a research report on Thursday, August 3rd. Deutsche Bank AG reiterated a “buy” rating and set a $273.00 price target (up from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Finally, BidaskClub upgraded Allergan PLC. from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Eight analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $274.49.

In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.36% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply